At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
BDNF Essentialsdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Exploratory Study to Investigate the Efficacy of BDNF Essentials® on Cognition in a Healthy Adult Population With Self-reported Memory Complaints
In Brief
A Phase 1 clinical trial evaluating BDNF Essentials for Cognitive Change. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The objective of this open-label, exploratory study is to investigate the efficacy of BDNF Essentials® on cognition in a healthy adult population with self-reported memory complaints. As there is a dearth of available literature on BDNF in this study population, the current study is designed to understand the role of BDNF to inform potential future studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Change
CountriesCanada
CollaboratorsKGK Science Inc.
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartApr 2021
Primary CompletionSep 2021
TodayJul 2026
First PostedApr 27, 2021
Enrollment StartApr 27, 2021
Primary CompletionSep 10, 2021
TodayJul 1, 2026
Enrollment to primary: 4 monthsPosted 5.2 years ago
Interventions
BDNF Essentialsdietary
Participants will take two capsules, twice daily with water for 84 days.